HTA collaboration in support of health system resilience

European network for Health Technology Assessment (EUnetHTA)

Luciana Ballini - BSc- MSc Chair of the EUnetHTA Plenary Assembly Agenzia Sanitaria e Sociale Regionale - Italy

I declare I have no conflicts of interest





The timeline of reaching a sustainable and permanent HTA cooperation in Europe





Participants in EUnetHTA JA2

EUnetHTA Partners and Associates

69 Partner organisations designated by Ministries of Health

Large number of regional agencies and non-for-profit organisations that produce or contribute to HTA





Health Technology Assessment

- * Health technology assessment (HTA) is a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related to the use of a health technology, in a systematic, transparent, unbiased, robust manner.
- * Its aim is to inform the formulation of safe, effective health policies that are patient focused and seek to achieve best value.
- * Despite its policy goals, HTA must always be firmly rooted in research and the scientific method.











How HTA can / does contribute to Health Systems' resilience





Expectations (and tensions)



Effective +
safe
technologies

Access and equity

Population wellbeing

Development competiitiveness

Economic growth and employment

 Unwitting means for profit OR recipients/users of effective innovations

 Best cost/benefit ratio OR undifferentiated expenditure ceilings

Health Systems Citizens/ clinicians



Developers



The Domains of the HTA Core Model®

- answering questions to aid decisions

HTA Core Model DOMAINS 1. Health problem and current use of Reliable, timely, transparent, information technology 2. Description and technical characteristics 3. Safety 4. Clinical effectiveness 5. Costs and economic evaluation 6. Ethical analysis 7. Organisational aspects 8. Social aspects 9. Legal aspects

Benefits + risks compared to one or more alternatives Clinical appropriatenss




Costs + economic impact
Sustainability



Organizational appropriateness Effective implementation



EUnetHTA Activities and Tools





The HTA European Collaboration goals



Efficiency

- Timely information
- Less duplication
- Re-use and local adaptation
- Greater coverage of topics

Quality

- Shared methodology
- New/emerging methodological challenges

Availability of evidence

- Communication of evidence needs
- Dealing with research gaps

Sharing trustworthy assessments

 Joint products, collaborative products, re-use of local products



HTA and context

Globalize the evidence, localize the decision



J.M. Eisenberg

Locate the decision, globalise the evidence, localise the reporting



EUnetHTA

The Domains of the HTA Core Model®

- global evidence for local decisions

HTA Core Model DOMAINS

- 1. Health problem and current use of technology
- 2. Description and technical characteristics
- 3. Safety
- 4. Clinical effectiveness
- 5. Costs and economic evaluation
- 6. Ethical analysis
- 7. Organisational aspects
- 8. Social aspects
- 9. Legal aspects

GLOBAL Evidence on TEC, EFF, SAF



GLOBAL

Methods of analysis - Endpoints



LOCAL

Target population/ Clinical practice Budget impact / Equity issues Organizational needs

Global evidence to support local decisions

- Ø Transparency and accountability of decisions
- Ø Variations explained and understood
- Ø Higher predictability of market and health expenditures
- Ø Increase of uniformity of care across borders



Key lessons learned

Value of network

- Ø Positive national results of European cooperation
- Ø Synergies between policy making, HTA and regulation have materialised at EU level they facilitate national synergies
- Ø Getting effective technologies faster to the patients pathways are emerging, with shared strategies still to be developed

The HTA cooperation mechanism

- Ø Europe has an official HTA Network Strategy
- Ø EUnetHTA has issued Recommendations on the implementation of the scientific work

JA 3 - Next goals / Objectives :

towards a permanent and sustainable cooperation

- Ø Recommendations for a sustainable model of European HTA
- Ø Sustainable joint work: from early assessment to re-assessment
- Ø Support for developers of medical technologies on their product development plans
- Ø Quality management / assurance of HTA products
- Ø Increase HTA capacity in MS
- Ø Better understanding of how HTA is/becomes embedded in decision making processes of MS



Thank you

This presentation arises from the EUnetHTA Joint Action 2 which has received funding from the European Union, in the framework of the Health Programme



